Therapy of AIDS-associated Kaposi's sarcoma: Targeting pathogenetic mechanisms

Hematology/Oncology Clinics of North America

Volumn 17, Issue 3, 2003, Pages 763-783

  Krown, Susan E ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ALITRETINOIN; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; CYTOKINE ANTIBODY; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; IM 862; INTEGRIN; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; ISOTRETINOIN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; PENTOSAN POLYSULFATE; REBIMASTAT; RECOMBINANT INTERLEUKIN 12; RETINOID; SEMAXANIB; TECOGALAN; THALIDOMIDE; VASCULOTROPIN;

AIDS RELATED COMPLEX; ALLERGIC REACTION; ANGIOGENESIS; ARTHRALGIA; CANCER GROWTH; CANCER REGRESSION; CARCINOGENESIS; CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; FEVER; HEADACHE; HUMAN; KAPOSI SARCOMA; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; POLYARTHRITIS; PRIORITY JOURNAL; RASH; REVIEW; SEDATION; SIDE EFFECT; SKIN TOXICITY;

EID: 0037710726     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00042-X     Document Type: Review

References (141)

1. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 1995;332:1181-5.
2. Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995;346:799-802.
3. de Lellis L, Fabris M, Cassai E, Corallini A, Giraldo G, Feo C, et al. Herpesvirus-like DNA sequences in non-AIDS Kaposi's sarcoma. J Infect Dis 1995;172:1605-7.
4. Rezza G, Andreoni M, Dorrucci M, Pezzotti P, Monini P, Zerboni R, et al. Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases. J Natl Cancer Inst 1999;91:1468-74.
5. Renwick N, Halaby T, Weverling GJ, Dukers NH, Simpson GR, Coutinho RA, et al. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS 1998;12:2481-8.
6. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998;338: 948-54.
7. Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, Saah A, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996;335:233-41.
8. Reitz Jr MS, Nerurkar LS, Gallo RC. Perspective on Kaposi's sarcoma: facts, concepts, and conjectures. J Natl Cancer Inst 1999;91:1453-8.
9. Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci USA 1996;93: 14862-7.
10. Jenner RG, Boshoff C. The molecular pathology of Kaposi's sarcoma-associated herpesvirus. Biochim Biophys Acta 2002;1602:1-22.
11. Zhong W, Wang H, Herndier B, Ganem D. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci USA 1996;93: 6641-6.
12. Ensoli B, Stürzl M, Monini P. Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Adv Cancer Res 2001;81:161-200.
13. Stürzl M, Zietz C, Monini P, Ensoli B. Human herpesvirus-8 and Kaposi's sarcoma: relationship with the multistep concept of tumorigenesis. Adv Cancer Res 2001;81:125-59.
14. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997;99:2082-6.
15. Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 1996;10:1101-5.
16. Jones JL, Hanson DL, Chu SY, Ward JW, Jaffe HW. AIDS-associated Kaposi's sarcoma. Science 1995;267:1078-9.
17. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999;340:1063-70.
18. Morfeldt L, Torssander J. Long-term remission of Kaposi's sarcoma following foscamet treatment in HIV-infected patients. Scand J Infect Dis 1994;26:749-52.
19. Robles R, Lugo D, Gee L, Jacobson MA. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. J Acquir Immune Defic Syndr 1999;20:34-8.
20. Wagstaff AJ, Bryson HM, Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994;48:199-226.
21. Shaw RN, Arbiser JL, Offermann MK. Valproic acid induces human herpesvirus 8 lytic gene expression in BCBL-1 cells. AIDS 2000;14:899-902.
22. Senderowicz AM. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 2002;7(Suppl 2):12-9.
23. Barillari G, Ensoli B. Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin Microbiol Rev 2002;15:310-26.
24. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, et al. Release, uptake and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993;67:277-87.
25. Barillari G, Sgadari C, Fiorelli V, Samaniego F, Colombini S, Manzari V, et al. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the α5β1 and αvβ3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood 1999;94:663-72.
26. Barillari G, Sgadari C, Palladino C, Gendelman R, Caputo A, Morris CB, et al. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the αvβ3 integrin. J Immunol 1999;163:1929-35.
27. Toschi E, Barillari G, Sgadari C, Bacigalupo I, Cereseto A, Carlei D, et al. Activation of matrix metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Mol Biol Cell 2001;12:2934-46.
28. Lafrenie RM, Wahl LM, Epstein JS, Yamada KM, Dhawan S, et al. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J Immunol 1997;159:4077-83.
29. Merat R, Amara A, Lebbe C, de The H, Morel P, Saib A. HIV-1 infection of primary effusion lymphoma cell line triggers Kaposi's sarcoma-associated herpesvirus (KSHV) reactivation. Int J Cancer 2002;97:791-5.
30. Harrington Jr W, Sieczkowski L, Sosa C, Chan-a-Sue S, Cai JP, Cabral L, et al. Activation of HHV-8 by HIV-1 tat. Lancet 1997;349:774-5.
31. Deregibus MC, Cantaluppi V, Doublier S, Brizzi MF, Deambrosis I, Albini A, et al. HIV-1-Tat protein activates phosphatidylinositol 3-kinase/AKT-dependent survival pathways in Kaposi's sarcoma cells. J Biol Chem 2002;277:25195-202.
32. Morini M, Benelli R, Giunciuglio D, Carlone S, Arena G, Noonan DM, et al. Kaposi's sarcoma cells of different etiologic origins respond to HIV-Tat through the Flk-1/KDR (VEGFR-2): relevance in AIDS-KS pathology. Biochem Biophys Res Commun 2000;273:267-71.
33. Prakash O, Tang ZY, He YE, Ali MS, Coleman R, Gill J, et al. Human Kaposi's sarcoma cell-mediated tumorigenesis in human immunodeficiency type 1 tat-expressing transgenic mice. J Natl Cancer Inst 2000;92:721-8.
34. Ariyoshi K, Schim van der Loeff M, Cook P, Whitby D, Corrah T, Jaffar S, et al. Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8. J Hum Virol 1998;1:193-9.
35. Wang QJ, Jenkins FJ, Jacobson LP, Kingsley LA, Day RD, Zhang ZW, et al. Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. Blood 2001;97:2366-73.
36. Sirianni MC, Vincenzi L, Topino S, Giovannetti A, Mazzetta F, Libi F, et al. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol 2002;32:2711-20.
37. Strickler HD, Goedert JJ, Bethke FR, Trubey CM, O'Brien TR, Palefsky J, et al. Human herpesvirus 8 cellular immune responses in homosexual men. J Infect Dis 1999;180:1682-5.
38. Emirhan I, Chandra A, Hasselmayer O, Biberfeld P, Chandra P. Detection of distinct patterns of anti-tat antibodies in HIV-infected individuals with or without Kaposi's sarcoma. J Acquir Immune Defic Syndr 1999;22:364-8.
39. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999;282:2220-6.
40. Jones JL, Hanson DL, Dworkin MS, Jaffe HW. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr 2000;24:270-4.
41. Lebbé C, Blum L, Pellet C, Blanchard G, Vérola O, Morel P, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998;12:F45-9.
42. Cattelan A, Calabro M, Gasperini P, Aversa S, Zanchetta M, Meneghetti F, et al. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 2001;28: 44-9.
43. Wilkinson J, Cope A, Gill J, Bourboulia D, Hayes P, Imami N. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol 2002;76:2634-40.
44. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8:225-32.
45. Pati S, Pelser CB, Dufraine J, Bryant JL, Reitz Jr MS, Weichold FF. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi's sarcoma. Blood 2002;99:3771-9.
46. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-94.
47. Monini P, Colombini S, Sturzl M, Goletti D, Cafaro A, Sgadari C, et al. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood 1999;93:4044-58.
48. Chang J, Renne R, Dittmer D, Ganem D. Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication. Virology 2000;266:17-25.
49. Sciacca FL, Sturzl M, Bussolino F, Sironi M, Brandstetter H, Zietz C, et al. Expression of adhesion molecules, platelet activating factor and chemokines by Kaposi's sarcoma cells. J Immunol 1994;153:4816-25.
50. Fiorelli V, Gendelman R, Samaniego F, Markham PD, Ensoli B. Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells. J Clin Invest 1995;95:1723-34.
51. Fiorelli V, Barillari G, Toschi E, Sgadari C, Monini P, Sturzl M, et al. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis. J Immunol 1999;162: 1165-70.
52. Samaniego F, Markham PD, Gallo RC, Ensoli B. Inflammatory cytokines induce AIDS-Kaposi's sarcoma (KS)-derived spindle cells to produce and release basic fibroblast growth factor and enhance KS-like lesion formation in nude mice. J Immunol 1995;154:3582-92.
53. Samaniego F, Markham PD, Gendelman R, Gallo RC, Ensoli B. Inflammatory cytokines induce endothelial cells to produce and release basic fibroblast growth factor and to promote Kaposi's sarcoma-like lesions in nude mice. J Immunol 1997;158:1887-94.
54. Louie S, Cai J, Law R, Lin G, Lunardi-Iskandar Y, Jung B, et al. Effects of interleukin-1 and interleukin-1 receptor antagonist in AIDS-Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovr 1995;8:455-60.
55. Miles SA, Rezai AR, Salazar-Gonzalez JF, Vander Meyden M, Stevens RH, Logan DM, et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 1990;87:4068-72.
56. Ensoli B, Nakamura S, Salahuddin SZ, Biberfeld P, Larsson L, Beaver B, et al. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 1989;243:223-6.
57. Watanabe K, Kinoshita S, Nakagawa H. Purification and characterization of cytokine-induced neutrophil chemoattractant produced by epithelioid cell line of normal rat kidney (NRK-52E cell). Biochem Biophys Res Commun 1989;161:1093-9.
58. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000;68:1-8.
59. Masood R, Cai J, Tulpule A, Zheng T, Hamilton A, Sharma S, et al. Interleukin 8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma. Clin Cancer Res 2001;7:2693-702.
60. Gershengorn MC, Geras-Raaka E, Varma A, Clark-Lewis I. Chemokines activate Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture. J Clin Investig 1998;102:1469-72.
61. Aboulafia D, Miles SA, Saks SR, Mitsuyasu RT. Intravenous recombinant tumor necrosis factor in the treatment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr 1989; 2:54-8.
62. Krigel RL, Padavic-Shaller KA, Rudolph AR, Poiesz BJ, Comis RL. Exacerbation of epidemic Kaposi's sarcoma with a combination of interleukin-2 and γ interferon: results of a phase 2 study. J Biol Response Mod 1989;8:359-65.
63. Mitsuyasu RT. Clinical aspects of AIDS-related Kaposi's sarcoma. Curr Opin Oncol 1993;5: 835-44.
64. Takebe N, Paredes J, Pino MC, Lownsbury WH, Agosti J, Krown SE. Phase I/II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients. J Interferon Cytokine Res 1998;18:321-6.
65. Corbeil J, Rappaport E, Richman DD, Looney DJ. Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells. J Clin Invest 1994;93:1981-6.
66. Guo WX, Gill PS, Antakly T. Inhibition of AIDS-Kaposi's sarcoma cell proliferation following retinoic acid receptor activation. Cancer Res 1995;55:823-9.
67. Ogata A, Nishimoto N, Shima Y, Yoshizaki K, Kishimoto T. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood 1994;84:3040-6.
68. Tsang KJ, Crowe DL. Retinoic acid and extracellular matrix inhibition of matrix metalloproteinase 9 expression is mediated by the mitogen activated protein kinase pathway. Int J Oncol 2001;18:369-74.
69. Bailey J, Pluda JM, Foli A, Saville MW, Bauza S, Adamson PC, et al. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. J Clin Oncol 1995;13:1966-74.
70. Gill PS, Espina BM, Moudgil T, Kidane S, Esplin JA, Tulpule A, et al. All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot phase II study. Leukemia 1994;8(Suppl 3):S26-32.
71. Saiag P, Pavlovic M, Clerici T, Feauveau V, Nicolas J-C, Emilie D, et al. Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid: results of a sequential non-randomized phase II trial. AIDS 1998;12:2169-76.
72. Bower M, Fife K, Landau D, Gracie F, Phillips RH, Gazzard BG. Phase II trial of 13-cis-retinoic acid for poor risk HIV-associated Kaposi's sarcoma. Int J STD AIDS 1997;8:518-21.
73. Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 1999;22:235-46.
74. Miles SA, Dezube BJ, Lee JY, Krown SE, Fletcher MA, Saville MW, et al. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 2002;16:421-9.
75. Dourado I, Martinez-Maza O, Kishimoto T, Suzuki H, Detels R. Interleukin 6 and AIDS associated Kaposi's sarcoma: a nested case control study within the Multicenter AIDS Cohort Study. AIDS Res Hum Retroviruses 1997;13:781-8.
76. Krown SE. Treatment of Kaposi's sarcoma: the role of interferon and thalidomide. Curr Opin Oncol 2001;13:374-81.
77. Makonkawkeyoon S, Limson-Pobre RNR, Moreira AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:5974-8.
78. D'Amato RJ, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5.
79. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998;236:461-6.
80. Stephens TD, Bunde CJ, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 2000;59:1489-99.
81. Haslett PAJ, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8 + subset. J Exp Med 1998;187:1885-92.
82. Corral LG, Haslett PAJ, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs which are potent inhibitors of TNF-α. J Immunol 1999;163:380-96.
83. Soler RA, Howard M, Brink NS, Gibb D, Tedder RS, Nadal D. Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin Infect Dis 1996;23:501-3.
84. Fife K, Howard MR, Gracie F, Phillips RH, Bower M. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998;9:751-5.
85. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000;18:2593-602.
86. Politi P, Reboredo G, Losso M, Vujacich C, Schwartsmann G, Lewi D. Phase I trial of thalidomide in AIDS-related Kaposi's sarcoma [abstract]. Proc Am Soc Clin Oncol 1998;17:41a.
87. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996;87:3877-82.
88. Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999;93:1612-21.
89. Geras-Raaka E, Varma A, Ho H, Gershengorn MC. Human interferon-γ-inducible protein 10 (IP-10) inhibits constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. J Exp Med 1998;188:405-8.
90. Little RF, Pluda JM, Wyvill K, Lietzau J, Shearer G, Tosato G, et al. Interleukin 12 (IL-12) appears to be active in AIDS-asociated Kaposi's sarcoma (KS): early results of a pilot study. Paper presented at the 7th Conference on Retroviruses and Opportunistic Infections [abstract #5]. San Francisco, January 30-February 2, 2000.
91. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93:178-93.
92. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999;103:1237-41.
93. Fingleton B, Matrisian LM. Matrix metalloproteinases as targets for therapy in Kaposi's sarcoma. Curr Opin Oncol 2001;13:368-73.
94. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2:737-44.
95. Meade-Tolin LC, Way D, Witte MH. Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells. Acta Histochem 1999; 101:305-16.
96. Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P, et al. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS 1994;8:1237-44.
97. Lamoreaux WJ, Fitzgerald MEC, Reiner A, Hasty KA, Charles ST. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998;55:29-42.
98. Cianfrocca M, Cooley TP, Lee JY, Rudeck MA, Ratner L, Pluda JM, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS Malignancy Consortium study. J Clin Oncol 2002;20:153-9.
99. Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 1999;43(Suppl):S61-8.
100. Barillari G, Gendelman R, Gallo RC, Ensoli B. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi's sarcoma and cytokine activated vascular cells induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 1993;90:7941-5.
101. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
102. 3. Cell 1996;85:683-93.
103. Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. Vascular endothelial growth factor/ vascular permeability factor is an autocrine factor for AIDS-Kaposi's sarcoma. Proc Natl Acad Sci USA 1997;94:979-84.
104. Nakamura S, Murakami-Mori K, Rao N, Weich H, Rajeev B. Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells. J Immunol 1997;158:4992-5001.
105. Comali E, Zietz C, Benelli R, Weninger W, Masiello L, Breier G, et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 1996;149:1851-69.
106. Brown LF, Tognazzi K, Dvorak HF, Harrist TJ. Strong expression of kinase insert domain containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 1996;148: 1065-74.
107. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
108. Arasteh K, Hannah A. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma. Oncologist 2000;5(Suppl 1):28-31.
109. Xerri L, Houssoun J, Planche J, Guigou V, Grob JJ, Parc P, et al. Fibroblast growth factor gene expression in AUDS-Kaposi's sarcoma detected by in situ hybridization. Am J Pathol 1991;138: 9-15.
110. Samaniego F, Markham PD, Gendelman R, Watanabe Y, Kao V, Kowalski K, et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 1998;152:1433-43.
111. Ensoli B, Markham P, Kao V, Barillari G, Fiorelli V, Gendelman R, et al. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS. J Clin Invest 1994;94:1736-46.
112. Pluda JM, Shay LE, Foli A, Tannenbaum S, Cohen PJ, Goldspiel BR, et al. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 1993;85:1585-92.
113. Tulpule A, Snyder JC, Espina BM, Higashi L, Satomi M, Lombardy EE, et al. A Phase I study of tecogalan, a novel angiogenesis inhibitor in the treatment of AIDS-related Kaposi's sarcoma and solid tumors [abstract]. Blood 1994;84(10, Suppl 1):248a.
114. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995;92:4562-6.
115. Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 1998;91:3289-99.
116. Staddon A, Henry D, Bonnem E. A randomized dose finding study of recombinant platelet factor 4 (rPF4) in cutaneous AIDS-related Kaposi's sarcoma (KS) [abstract]. Proc Am Soc Clin Oncol 1994;13:A3.
117. Northfelt DW, Robles R, Lang W, Wagner B, Kahn J, Bonnem E. Phase I/II study of IV recombinant platelet factor 4 (rPF4) in AIDS-related Kaposi's sarcoma (AIDS-KS) [abstract]. Proc Am Soc Clin Oncol 1995;14:820.
118. Lozano RM, Redondo-Horcajo M, Jimenez MA, Zilberberg L, Cuevas P, Bikfalvi A, et al. Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic activity. J Biol Chem 2001;276:35723-34.
119. Hagedorn M, Zilberberg L, Lozano RM, Cuevas P, Canron X, Redondo-Horcajo M, et al. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J 2001;15:550-2.
120. Sin N, Meng L, Wang MQ, Wen JJ, Bommann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 1997;94:6099-103.
121. Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci USA 2000;97:6427-32.
122. Dezube BJ, VonRoenn JH, Holden Wiltse J, Cheung TW, Remick SC, Cooley TP, et al. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 1998;16:1444-9.
123. Taddei L, Chiarugi P, Brogelli L, Cirri P, Magnelli L, Raugei G, et al. Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Biochem Biophys Res Commun 1999;263: 340-5.
124. Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY, Lee ST, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002;277:27872-9.
125. Hajitou A, Grignet-Debrus C, Devy L, Berndt S, Blacher S, Deroanne CF, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 2002;16:1802-4.
126. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, et al. Endostatin inhibits endothelial and tumor cell invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000;60:5410-3.
127. Hanai J, Dhanabal M, Karumanchi SA, Albanese C, Waterman M, Chan B, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin DI. J Biol Chem 2002;277: 16464-9.
128. Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin alpha 5 beta 1 and caveolin-1 and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 2002;62:5580-9.
129. Rehn M, Veikkola T, Kuk-Valdre E, Nakamura H, Ilmonen M, Lombardo CR, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 2001;98:1024-9.
130. Investigator Brochure. IM862 (small peptide). Kirkland (WA): Cytran Ltd. C/o Cytran Inc.
131. Tulpule A, Scadden DT, Espina BM, Cabriales S, Howard W, Shea K, et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 2000;18:716-23.
132. Noy A, Gill P, Scadden D, Lee J, Dezube B, Aboulafia D, et al. Angiogenesis inhibitor IM862 is ineffective against AIDS-KS in a randomized, placebo controlled trial [abstract]. Presented at the Sixth International Conference on Malignancies in AIDS and Other Immunodeficiencies: Basic, Epidemiologic and Clinical Research. Bethesda, MD, April 22-24, 2002.
133. Gill PS, Lunardi-Iskandar Y, Louie S, Tulpule A, Zheng T, Espina BM, et al. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med 1996;335:1261-9 [published errata appears in N Engl J Med 1997;336:60 and 1997;336:1115].
134. Gill PS, McLaughlin T, Espina BM, Tulpule A, Louie S, Lunardi-Iskander Y, et al. Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency-related mucocutaneous Kaposi's sarcoma. J Natl Cancer Inst 1997;89:1797-802.
135. Darzynkiewicz Z. The butler did it: search for killer(s) of Kaposi's sarcoma cells in preparations of human chorionic gonadotropin. J Natl Cancer Inst 1999;91:104-6.
136. Bekker L-G, Haslett P, Maartens G, et al. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. J Inf Dis 2000;181:954-65.
137. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:247-57.
138. Kaplan G, Thomas S, Fierer DS, et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses 2000;16:1345-55.
139. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336:1487-93.
140. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 1996;10:1501-7.
141. Krown SE, Li P, Von Roenn JH, Paredes J, Huang J, Testa MA. Randomized, open-label, phase II AIDS Clinical Trials Group study of two doses of interferon alfa-2b combined with didanosine in patients with AIDS-associated Kaposi's sarcoma: Efficacy of daily low-dose interferon. J Interferon Cytokine Res 2002;22:295-303.